TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22445432

Group type: EXPERIMENTAL
Intervention: Male condom
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Female condom
Number of subjects: 108
Study: 20169410

Group type: EXPERIMENTAL
Intervention: Alcohol PBI
Number of subjects: 978

Group type: EXPERIMENTAL
Intervention: Enhanced Alcohol + Sex PBI
Number of subjects: 978

Group type: COMPARATOR
Intervention: Control
Number of subjects: 978

Group type: COMPARATOR
Intervention: Unmeasured Control
Number of subjects: 978
Study: 17888558

Group type: EXPERIMENTAL
Intervention: 500‐mg GTPs
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 1000‐mg GTPs
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 15950853

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with 1.0% ropivacaine with 1:200,000 epinephrine and analgesia with 0.2% ropivacaine at 8 mL/h, maintained for 7 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Spinal anesthesia with 0.5% bupivacaine and analgesia with intravenous patient‐controlled analgesia morphine, demand mode only
Number of subjects: 38
Study: 12703832

Group type: EXPERIMENTAL
Intervention: Propofol (Group Propo)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Methohexital and Isoflurane (Group Metho-Iso)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dreaming patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Non-dreaming patients
Number of subjects: 50
Study: 10569604

Group type: EXPERIMENTAL
Intervention: 0.4 mg desmopressin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 0.8 mg desmopressin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Anticholinergic treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 8935931

Group type: EXPERIMENTAL
Intervention: Diazepam (0.03 mL/Kg of 5 mg/mL solution)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 100
Study: 1714886

Group type: EXPERIMENTAL
Intervention: Amsacrine (AMSA) at 100 mg/M2 daily for 5 days and etoposide at 200 mg/M2 daily for the first 3 days of therapy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Amsacrine (AMSA) and etoposide plus azacitidine (AZ) at a dosage of 250 mg/M2 on days 4 and 5
Number of subjects: 57

Group type: COMPARATOR
Intervention: Amsacrine (AMSA) and etoposide
Number of subjects: 57
Study: 6349288

Group type: EXPERIMENTAL
Intervention: Covert extinction
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Waiting list group (Control)
Number of subjects: 21
Study: 31318261

Group type: EXPERIMENTAL
Intervention: Parenting Time (PT)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Interparental Conflict (IPC)
Number of subjects: 141
Study: 30326035

Group type: EXPERIMENTAL
Intervention: Culturally tailored patient navigator intervention
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 223
Study: 27264120

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 1918

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1918
Study: 25201459

Group type: EXPERIMENTAL
Intervention: tamsulosin 0.4 mg for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo for 4 weeks
Number of subjects: 60
Study: 22240282

Group type: EXPERIMENTAL
Intervention: sorafenib 400mg bid
Number of subjects: 226

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 226
Study: 19729318

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Number of subjects: 157

Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 157
Study: 17403742

Group type: EXPERIMENTAL
Intervention: Self-etch (SE) adhesive
Number of subjects: 25

Group type: COMPARATOR
Intervention: Etch-and-rinse (ER) adhesive
Number of subjects: 25
Study: 15829478

Group type: EXPERIMENTAL
Intervention: Higher incentives group (Can dollars 15 electronic gift certificate)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lower incentive group (Can dollars 5 gift certificate)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: General Internet community (not specified incentive)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Friend referrals (snowball strategy)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Defined community recruitment (Can dollars 20 electronic gift certificate)
Number of subjects: 14
Study: 12441222

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Quinapril (10 mg)
Number of subjects: 30
Study: 9653491

Group type: EXPERIMENTAL
Intervention: Amifostine + RCT (n = 25)
Number of subjects: 39

Group type: COMPARATOR
Intervention: RCT alone (n = 14)
Number of subjects: 39
Study: 8593193

Group type: EXPERIMENTAL
Intervention: 0.454% SnF2 stabilized with 2.08% sodium gluconate
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: 0.454% SnF2 stabilized with 4.16% sodium gluconate
Number of subjects: 549

Group type: COMPARATOR
Intervention: 0.243% NaF control dentifrice
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: 0.454% SnF2 dentifrices
Number of subjects: 549
Study: 2669536

Group type: EXPERIMENTAL
Intervention: Left unilateral ECT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Right unilateral ECT
Number of subjects: 30
Study: 1225368

Group type: EXPERIMENTAL
Intervention: 75 dB, 1000 Hz orienting tones (condition 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 75 dB, 1000 and 2000 Hz tones requiring a motor response to the 1000 Hz tone (signal tone, condition 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 85 dB, 1000 Hz orienting tones (condition 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 75 dB tones (control group for non-psychotic psychiatric patients)
Number of subjects: 0
Study: 31941548

Group type: EXPERIMENTAL
Intervention: Vaping cues (exposure to vaping videos)
Number of subjects: 936

Group type: COMPARATOR
Intervention: Neutral cues (exposure to neutral videos)
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Smoking cues (exposure to smoking videos)
Number of subjects: 936
Study: 31060627

Group type: COMPARATOR
Intervention: OLV + CPAP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OLV + DLV
Number of subjects: 30
Study: 27811309

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (combined aspirin, clopidogrel, and dipyridamole)
Number of subjects: 3096

Group type: COMPARATOR
Intervention: Guideline treatment (control group)
Number of subjects: 3096
Study: 27827816

Group type: EXPERIMENTAL
Intervention: Olaratumab combined with doxorubicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 0
Study: 24763910

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22205191

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 60
Study: 19416499

Group type: EXPERIMENTAL
Intervention: Zinc (Zn) only
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Zinc and Copper (Zn+Cu)
Number of subjects: 808

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 808
Study: 17950796

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15752381

Group type: EXPERIMENTAL
Intervention: Ebastine + Ketoconazole (20 mg qd + 450 mg qd)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Loratadine + Ketoconazole (10 mg qd + 400 mg qd)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Ketoconazole + Placebo (450 mg qd or 400 mg qd)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Ebastine + Placebo (20 mg qd)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Loratadine + Placebo (10 mg qd)
Number of subjects: 117
Study: 12110818

Group type: EXPERIMENTAL
Intervention: HFA‐BDP Autohaler at half the daily dose (100-200 microg)
Number of subjects: 520

Group type: COMPARATOR
Intervention: CFC‐BDP+S (200-400 microg)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Both groups (HFA‐BDP and CFC‐BDP+S)
Number of subjects: 520
Study: 10195546

Group type: EXPERIMENTAL
Intervention: Sevoflurane 8%
Number of subjects: 76

Group type: COMPARATOR
Intervention: Propofol 3 mg/kg
Number of subjects: 76
Study: 7773026

Group type: EXPERIMENTAL
Intervention: Mutual support program
Number of subjects: 113

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 113

Group type: COMPARATOR
Intervention: Married men
Number of subjects: 113
Study: 1971629

Group type: EXPERIMENTAL
Intervention: Perineal colonization by coliforms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bacteriuria
Number of subjects: 0
Study: 7428401

Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg, 1 dose
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg, 7 doses
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cefuroxime 1.5 g, 1 dose
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cefuroxime 1.5 g, 7 doses
Number of subjects: 49
Study: 31330250

Group type: EXPERIMENTAL
Intervention: HEART score with 50% compliance and 0% informed deviation (ID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HEART score with any compliance and at least 50% ID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HEART score with higher compliance and ID scenarios
Number of subjects: 0
Study: 28701627

Group type: EXPERIMENTAL
Intervention: Typing I (keyboard slope 0°)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Typing II (keyboard slope 20°)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no typing)
Number of subjects: 15
Study: 25446600

Group type: EXPERIMENTAL
Intervention: KRG-30% extract
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: AG-50% extract
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (cornstarch)
Number of subjects: 13
Study: 23548545

Group type: EXPERIMENTAL
Intervention: Locomotor training program (LTP)
Number of subjects: 469
Study: 21679530

Group type: EXPERIMENTAL
Intervention: Silastic septal splint
Number of subjects: 40
Study: 18938041

Group type: EXPERIMENTAL
Intervention: Females with CAH
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Males with CAH
Number of subjects: 128

Group type: COMPARATOR
Intervention: Unaffected females
Number of subjects: 128

Group type: COMPARATOR
Intervention: Unaffected males
Number of subjects: 128
Study: 17125424

Group type: EXPERIMENTAL
Intervention: Lactobacillus intravaginal capsule
Number of subjects: 424

Group type: COMPARATOR
Intervention: Placebo intravaginal capsule
Number of subjects: 424
Study: 14702508

Group type: EXPERIMENTAL
Intervention: One-page summary of clinical practice guidelines
Number of subjects: 3293

Group type: EXPERIMENTAL
Intervention: One-page summary of clinical practice guidelines and a reminder
Number of subjects: 3293

Group type: COMPARATOR
Intervention: No intervention (controls)
Number of subjects: 3293

Group type: EXPERIMENTAL
Intervention: Overall prescription rates (all groups)
Number of subjects: 3293
Study: 10357054

Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 39
Study: 8533342

Group type: EXPERIMENTAL
Intervention: Human object-recognition efficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factors affecting recognition efficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other factors affecting recognition efficiency
Number of subjects: 0
Study: 2039190

Group type: EXPERIMENTAL
Intervention: Schedule 2 (30 mg/kg over 2 days; one dose of 10 mg/kg followed by two doses of 5 mg/kg at 6‐h intervals on the first day and two doses of 5 mg/kg at 12‐h intervals on the second day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Schedule 2
Number of subjects: 27

Group type: COMPARATOR
Intervention: Schedule 1 (25 mg/kg over 3 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Schedule 1
Number of subjects: 27
Study: 6165255

Group type: EXPERIMENTAL
Intervention: Human albumin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextran 60
Number of subjects: 0
Study: 31793465

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (200 mL of tap water)
Number of subjects: 30
Study: 28947390

Group type: EXPERIMENTAL
Intervention: TTM at 33°C
Number of subjects: 163

Group type: COMPARATOR
Intervention: TTM at 36°C
Number of subjects: 163
Study: 24606094

Group type: EXPERIMENTAL
Intervention: ω-3 FAEE supplementation (4 g/d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hypocaloric diet alone (Control)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both interventions (ω-3 FAEE and control)
Number of subjects: 25
Study: 22500390

Group type: EXPERIMENTAL
Intervention: Busui Shengxue Granule (BSSXG)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Zaizao Shengxue Tablet (ZST)
Number of subjects: 124
Study: 20598391

Group type: EXPERIMENTAL
Intervention: Intensive information package (written information and a telephone call from the research nurse)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Standard consultation
Number of subjects: 194
Study: 17559735

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa correction/maintenance dosing (4.5 microg/kg weekly for 4 weeks followed by 4.5 microg/kg every 3 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Darbepoetin alfa weekly dosing (2.25 microg/kg weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa correction/maintenance dosing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Darbepoetin alfa weekly dosing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 16127110

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meals for dinner
Number of subjects: 34
Study: 12383323

Group type: EXPERIMENTAL
Intervention: SAE-HyCoSy with Levovist contrast medium and maximum acoustic power
Number of subjects: 41

Group type: COMPARATOR
Intervention: HSG (X-ray hysterosalpingography)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: SAE-HyCoSy
Number of subjects: 41
Study: 10408592

Group type: EXPERIMENTAL
Intervention: Eprosartan (200 or 300 mg b.i.d.)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Enalapril (5‐20 mg u.i.d.)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Eprosartan
Number of subjects: 528

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 528
Study: 7677298

Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg administered alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dapsone 100 mg administered with didanosine placebo tablets (group 1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dapsone 100 mg administered with active didanosine tablets (group 2)
Number of subjects: 12
Study: 1698170

Group type: EXPERIMENTAL
Intervention: Argon laser panretinal photocoagulation (PRP)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Non-lasered eyes (control group)
Number of subjects: 123
Study: 6754492

Group type: EXPERIMENTAL
Intervention: 50 g oral glucose tolerance test
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standardized breakfast meal of equivalent carbohydrate content
Number of subjects: 19
Study: 31905410

Group type: EXPERIMENTAL
Intervention: Amniotic suspension allograft injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0
Study: 27662576

Group type: EXPERIMENTAL
Intervention: 100-kVp Sn protocol
Number of subjects: 75

Group type: COMPARATOR
Intervention: 70-kVp protocol
Number of subjects: 75
Study: 27132075

Group type: EXPERIMENTAL
Intervention: Healthlines Depression Service plus usual care
Number of subjects: 609

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 609
Study: 25063416

Group type: EXPERIMENTAL
Intervention: HMZ-T2 head-mounted display
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wrap1200 head-mounted display
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed-site monitor
Number of subjects: 0
Study: 21986184

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No access to fluids (NF)
Number of subjects: 12
Study: 19499845

Group type: EXPERIMENTAL
Intervention: Myo-inositol plus folic acid
Number of subjects: 42
Study: 17498420

Group type: EXPERIMENTAL
Intervention: 0.2 percent minocycline mouthwash
Number of subjects: 17

Group type: COMPARATOR
Intervention: 0.25 percent tetracycline aqueous solution mouthwash
Number of subjects: 17
Study: 18005429

Group type: EXPERIMENTAL
Intervention: 5 mg of folic acid
Number of subjects: 730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study: 15160440

Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg (R20)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg (R10)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Loratadine 10 mg (L10)
Number of subjects: 339
Study: 11129253

Group type: EXPERIMENTAL
Intervention: Cold water exposure for patients with ET
Number of subjects: 40

Group type: COMPARATOR
Intervention: Warm water exposure for patients with ET
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Warm water exposure for patients with PD
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cold water exposure for patients with PD
Number of subjects: 40
Study: 9190233

Group type: EXPERIMENTAL
Intervention: Exposure to organic dust and microorganisms
Number of subjects: 31
Study: 1385586

Group type: EXPERIMENTAL
Intervention: Clodronate (3.2 g for the first month, thereafter 1.6 g)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Clodronate (3.2 g and 1.6 g)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Clodronate (3.2 g)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Clodronate and Placebo
Number of subjects: 75
Study: 6719513

Group type: EXPERIMENTAL
Intervention: Computerized tomography for localization of treatment volume
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional localization for treatment volume
Number of subjects: 55
Study: 30808670

Group type: EXPERIMENTAL
Intervention: Surgical fasciectomy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Collagenase injection
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 56
Study: 29278896

Group type: EXPERIMENTAL
Intervention: Eteplirsen
Number of subjects: 12
Study: 27296126

Group type: EXPERIMENTAL
Intervention: Triclosan‐coated polyglactin 910 with 2‐octylcyanoacrylate‐based adhesive (group 1)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Non‐triclosan‐coated polyglactin 910 (group 2)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Combined preventive measures (CPM) including antibiotic prophylaxis with IV amoxicillin/clavulanate (1.2 g)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (AP)
Number of subjects: 322
Study: 25186922

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 1049
Study: 21983238

Group type: EXPERIMENTAL
Intervention: Erotic video clip
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Humorous video clip
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aggressive video clip
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Training motivational video clip
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sad video clip
Number of subjects: 12

Group type: COMPARATOR
Intervention: Neutral control video clip
Number of subjects: 12
Study: 19618659

Group type: EXPERIMENTAL
Intervention: School-based fitness program
Number of subjects: 35
Study: 17804941

Group type: EXPERIMENTAL
Intervention: Telephone intervention as supportive nursing care
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no telephone intervention)
Number of subjects: 51
Study: 15156418

Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia (TIVA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Balanced anaesthesia (BA)
Number of subjects: 52
Study: 11642085

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg
Number of subjects: 213

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 213
Study: 9840720

Group type: EXPERIMENTAL
Intervention: Corticosteroid co-medication
Number of subjects: 87

Group type: COMPARATOR
Intervention: Docetaxel without corticosteroid co-medication
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cumulative dose of docetaxel
Number of subjects: 87
Study: 8030804

Group type: EXPERIMENTAL
Intervention: nedocromil sodium, 2% ophthalmic solution, bid
Number of subjects: 86

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 86
Study: 2723121

Group type: EXPERIMENTAL
Intervention: Traxanox sodium
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30903806

Group type: EXPERIMENTAL
Intervention: Outpatient treatment of severe wasting
Number of subjects: 1542
Study: 27696393

Group type: EXPERIMENTAL
Intervention: 3hC+ (3-hour MAL application with curettage)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 21hC- (21-hour MAL application without curettage)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 21hC+ (21-hour MAL application with curettage)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 3hC- (3-hour MAL application without prior curettage)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Extended MAL application with and without curettage
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pain and erythema
Number of subjects: 22
Study: 25447557

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine at 1 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intranasal fentanyl at 1.5 μg/kg
Number of subjects: 80
Study: 24411639

Group type: EXPERIMENTAL
Intervention: Docetaxel plus nintedanib
Number of subjects: 1314
Study: 22963131

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine/Cisplatin (Gem/Cis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pemetrexed/Cisplatin (Pem/Cis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel/Carboplatin (Pac/Carb)
Number of subjects: 0